Medexus Pharmaceuticals (TSE:MDP - Get Free Report) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of C$0.03 per share for the quarter.
Medexus Pharmaceuticals (TSE:MDP - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported C$0.11 EPS for the quarter, beating the consensus estimate of C$0.04 by C$0.07. The business had revenue of C$37.33 million for the quarter, compared to the consensus estimate of C$36.95 million. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%.
Medexus Pharmaceuticals Price Performance
Shares of TSE:MDP traded down C$0.16 during trading on Thursday, hitting C$2.39. 27,620 shares of the company were exchanged, compared to its average volume of 40,959. The company has a market cap of C$58.63 million, a PE ratio of 50.40 and a beta of 1.96. The stock has a 50 day moving average of C$2.57 and a 200 day moving average of C$2.14. Medexus Pharmaceuticals has a 52-week low of C$1.44 and a 52-week high of C$3.16.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on MDP shares. Stifel Nicolaus increased their target price on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a "buy" rating in a research report on Thursday, August 22nd. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the stock a "speculative buy" rating in a research report on Monday, September 30th. Finally, Stifel Canada upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research report on Monday, August 12th.
Read Our Latest Report on Medexus Pharmaceuticals
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
